The 37 countries and areas of the World Health Organization (WHO) Western Pacific Region have been preventing measles through ''control'' from 1990 to 1995, ''accelerated control'' from 1996 to 2002, and ''elimination'' from 2003 to now [1] . In 2005, the Regional Committee of the WHO Western Pacific Region established 2012 as the target date for regional measles elimination [2] . Measles elimination is defined as the absence of endemic measles transmission in a defined geographical area for R12 months in the presence of a well performing surveillance system [3] . Key strategies for measles elimination include (1) very high vaccination coverage (R 95%) with a first and second dose of measles-containing vaccine (MCV1 and MCV2) through routine immunization or catch-up and follow-up supplementary immunization activities (SIAs) (A catch-up SIA is an initial nationwide vaccination campaign that usually targets all children aged 9 months-14 years; follow-up SIAs are campaigns that usually target susceptible birth cohorts since the previous SIA (usually children reaching 9 months of age after the prior SIA); (2) high quality case-based measles surveillance; and (3) use of a WHO-accredited measles laboratory network to confirm or discard suspected measles cases and identify measles virus genotypes. This report summarizes progress and challenges for achieving measles elimination in the Western Pacific Region, as of 2010.
METHODS
Indicators for monitoring progress toward measles elimination have been described and include routine measles immunization coverage, measles surveillance performance, and measles incidence [3] . Regional MCV1 coverage by year was determined using WHO/UNICEF estimates of vaccination coverage as of 2010 and, when these estimates were not available (such as in certain areas of Member States), with country estimates as reported in WHO/UNICEF Joint Reporting Forms [4] . Regional coverage was then determined by weighting national coverage by population size based on United Nations estimates [5, 6] ; Pitcairn Islands (population ,100) does not report data to WHO/UNICEF and is not included in this report. MCV2 and SIA coverage were determined from country estimates as reported in the Joint Reporting Form. MCV may include measles, mumps, rubella vaccine (MMR), measles-rubella vaccine (MR), measles-mumps vaccine (MM), or single antigen measles vaccine (M). Regional averages of routine and supplementary immunization coverage data and data from China were calculated independently, as China represents 75% of the region's population.
Aggregate and case-based measles surveillance data have been submitted from some countries and areas to the WHO Regional Office for the Western Pacific (WPRO) regularly since 2002. In 2007, WPRO requested each country and area submit monthly case-based surveillance data. In 2008, WPRO also requested each national measles laboratory (NML) submit selected case-based epidemiologic and laboratory data monthly. WPRO considers a report timely if it is received by the requested date, and complete if it is received any time before the deadline for the next scheduled report. Standard definitions of suspected, confirmed, and discarded measles cases, and indicators and targets of case-based measles surveillance performance including reporting rates, adequate case investigation, adequate specimen collection, and timeliness of laboratory reporting of serological test results, have been described [3] . Second-level administrative units were those immediately below the national level.
Measles incidence and mortality rates and case fatality ratios (CFRs) were calculated using numerator data submitted by countries and areas through Joint Reporting Forms or by monthly case based surveillance reports, whichever was greater. Population-based denominators were based on UN estimates [4] . Tables 1 and 2 .
RESULTS

Routine Immunization
Reporting Rates. The discarded measles rate among 32 countries and areas from which data were available in 2009 was 2.8 per 100,000 population, an increase from 1.6 in 2008 (target R2). However, performance was not uniform. Among 32 countries and areas reporting case-based data on suspected cases (China and Pitcairn Island do not report case-based data, Australia, Singapore, and New Zealand report confirmed cases only but not suspected or discarded cases), 8 (25%) achieved the target rate and another 3 nearly reached the target with 1.2-1.6 discarded cases per 100,000 population. The percentage of second-level administrative units with at least 1 discarded measles case per 100,000 population increased from 31% in 2008 to 43% in 2009. 5 countries or areas achieved the 80% target, and another nearly achieved the target with 78% of second-level administrative units reporting a discarded rate of at least 1 per 100,000.
Adequate Case Investigation. Laboratory Results Within 7 Days. The percentage of specimens with laboratory results reported within 7 days after specimen receipt decreased to 60% in 2009 compared with 76% in 2008 (target R 80%). Among 12 countries and areas with data available to calculate this indicator, 9 (75%) achieved the target. Reasons for decreased timeliness in providing laboratory results, particularly in Cambodia and Viet Nam, included (1) very large numbers of suspected measles cases with specimens, (2) difficulties in timely procurement of testing kits, and (3) the need for measles laboratory staff to test specimens for pandemic influenza (H1N1) in 2009.
Laboratory Network
The Western Pacific Region measles and rubella laboratory network (LabNet) performs critical functions for measles elimination by confirming or discarding suspected measles cases, identifying measles genotypes, and helping to determine potential geographic routes of transmission. The LabNet has grown to include a total of 383 laboratories, including 1 WHO global specialized laboratory (GSL) in Japan; 3 WHO regional reference laboratories (RRLs) in Australia, China, and Hong Kong; 17 fully functional national measles-rubella laboratories (NMLs) including the 3 RRLs; and, in China, 31 provincial and 331 prefecture laboratories.
As of May 2010, among 48 fully functional NMLs (N 5 17) and provincial laboratories in China (N 5 31), 45 were fully accredited by WHO based on site reviews and other performance criteria. All network laboratories in the region passed proficiency tests in 2008-2009. In 2009, concordance rates of measles serologic confirmatory testing results from 12 NMLs with data were .90% for each NML.
The LabNet tests many specimens annually. In 2008, Western Pacific Region network laboratories tested 115,973 and 32,311 samples for measles and rubella, respectively. In 2009, 61,100, and 25,834 samples were tested for measles and rubella, respectively. [7] . Japan did not implement elimination strategies and experienced another large outbreak affecting both adults and children in 2007-2008 [8] . Intensification of measles elimination activities, particularly in China and Japan, resulted in a 58% decrease in regional measles incidence from 82 cases per million population in 2008 to 34 cases per million population in 2009, the lowest ever reported. Table 3 lists the number of suspected and confirmed measles cases and incidence, by year and country or area, from 2007 to 2009. Table 4 provides specific case classification and outcome data, by country or area, for 2009. In China, the number of Particularly high percentages of clinically confirmed cases were reported in 2009 in Cambodia (87%), Hong Kong (China) (59%), and the Philippines (55%), suggesting that actual measles incidence in these places may be lower than reported. Overall, 2210 (25%) of 8836 confirmed cases from the Western Pacific Region (not including those from China, which does not report method of confirmation) were confirmed clinically.
Measles virus genotypes endemic to the Western Pacific Region since 2007 include, at minimum, H1, D5, and D9. Measles H1 genotype has been endemic in China and Vietnam, and since 2007 it also has been detected in Hong Kong (China), Republic of Korea, Lao People's Democratic Republic, Macau (China), New Zealand, and Australia. D5 strains have been endemic in Japan at least since 2007 and have been detected in Australia and Singapore. D9 genotype has been endemic in the Philippines at least since 2007 and has been detected in Singapore, Japan, Malaysia, New Zealand, Australia, China, Hong Kong (China), Cambodia, and Lao People's Democratic Republic. Other genotypes have also been identified in the This indicator has been computed using data from laboratory reports.
region. G3 was identified in the Philippines and New Zealand in 2007, and D4 was detected sporadically in Singapore, Australia, Japan, China, and New Zealand. As suggested from these data, countries in the Western Pacific Region are increasingly detecting imported measles virus genotypes from other countries in this and other regions. In 2009, Australia identified at least 4 measles genotypes from 34 imported cases and 62 importrelated cases from at least 13 countries in all 6 WHO regions. Estimates of measles deaths using a natural history model indicated that in 2008 the number of measles deaths in the Western Pacific Region was 2000 compared with 25,000 in the year 2000, a 92% decrease [9] . Only 53 deaths (CFR 5 0.09%) were reported from the Western Pacific Region in 2009 (Table 4) , a 54% decrease from the 116 deaths reported in 2008. However, measles deaths are likely to be underreported and CFRs understated because deaths occurring from respiratory and gastrointestinal superinfections after apparent recovery from measles are unlikely to be reported as measles deaths.
DISCUSSION
Increased coverage through routine and supplementary immunization activities has resulted in dramatic reductions in measles incidence and mortality in the Western Pacific Region. Improved surveillance performance (eg, reporting and adequate specimen collection indicators) in the region increases confidence that reported reductions in measles incidence and mortality are real, that countries are increasingly able to detect new or continuing chains of measles virus transmission in a timely manner, and that the region is indeed making substantial progress toward the 2012 measles elimination goal.
Countries and areas must closely follow the evolving epidemiology of measles and remain vigilant about identifying and investigating suspected measles cases. Intensified surveillance during the 2007 outbreak in the Republic of Korea demonstrated (1) the ongoing risk of measles among infants and young children caused by failure to provide scheduled measles vaccine doses on time, (2) the interplay of nosocomial and community-based measles virus transmission, and (3) criticality of high-quality case-based, laboratory-supported surveillance to monitor elimination status and track importations [10] . Surveillance data from Viet Nam during its epidemic beginning in 2008 revealed the role of young adults in initiating and propagating a measles epidemic that later primarily affected children, and the risk of accumulation of susceptible children with an MCV2 schedule at 6 years [11] .
The 4 member states with the highest populations in the region (China, Japan, Philippines, and Viet Nam) remain at risk for not achieving the 2012 goal, and each is taking significant actions customized to local needs and resources. China conducted a nationwide SIA that reached .102 million children during a 10-day period in September 2010. Special efforts were made to vaccinate migrant ''floating population'' children and other high-risk groups that account for a large percentage of measles cases in many provinces. Special strategies to vaccinate young adults that account for a large proportion of cases in some large cities in eastern China are being developed for 2011.
Japan's response to its large measles outbreak involving adolescents and young adults and then increasingly children aged 1-4 years was to develop and implement a 5-year measles elimination plan beginning in 2008 that (1) intensified efforts to achieve high vaccination coverage among children and young adults, including a 5-year rolling SIA that targeted persons aged 13 and 18 years for 5 consecutive years; (2) established nationwide case-based measles and rubella surveillance to replace the prior sentinel system; (3) designated measles and rubella laboratory reference centers for serologic testing; and (4) established national and local measles elimination councils to provide oversight and monitor progress toward elimination [7] . Transmission of measles virus in the Philippines has increased from 2008 to 2010 despite a national SIA in the last quarter of 2007 that reportedly vaccinated 95% of children aged 9-48 months. Age distribution of confirmed cases indicates that 75% of confirmed cases in 2009-2010 were ,8 years old and that immunization gaps exist among children aged 3-7 years that should have been protected by the 2007 SIA [12] . Young adults represent a small percentage of cases. The Philippines is planning to target all children aged 9 months to 7 years 11 months during its next SIA in April and May 2011.
The epidemic in Viet Nam that began in 2008 among unprotected university students in Hanoi evolved to affect primarily children aged ,7 years and has continued into 2010. From October 2008 through January 2010, incidence was highest among children aged 1-4 years (339 cases per million population), followed by infants (273 per million) and young adults aged 20-24 years (271 per million) [10] . Viet Nam conducted its second nationwide SIA in the last quarter of 2010, targeting children aged 1-5 years to be followed by a change in the scheduled age of routine MCV2 administration from 6 years to 18-24 months in 2011. Special strategies to target highrisk adults are being considered for 2011.
The American and European regions of WHO have conducted SIAs targeting adults as well as children to eliminate measles and rubella. Target age groups often have included persons #40 years of age. In contrast, many countries and areas of the Western Pacific Region introduced MCV into their immunization programs in the 1980s and conducted catch-up SIAs targeting children #14 years of age from 1996 to 2003 [6] . Will establishing high population-immunity in birth cohorts up [8] to 20-25 years of age be sufficient to prevent sustained future transmission among older age groups or between older age groups and susceptible children in the Western Pacific Region? Protecting children aged #15 years was effective in interrupting transmission among adults in outbreaks in Sao Paulo, Brazil, and Peru in the 1990s [13, 14] . Achieving measles elimination in all countries of the Western Pacific Region by 2012 will be a challenge for reasons other than changing epidemiology. National MCV1 and MCV2 coverage remains below 95% in several countries, and is very low in those with limited public health infrastructures. Immunization coverage at subnational levels may be low in many more countries and areas. Measles SIAs provide opportunities to address inequities in coverage and achieve uniformly high coverage throughout countries, thereby interrupting measles virus transmission. Quality assurance of measles SIAs is a priority, with local-level rapid coverage assessments and follow-up immunization conducted in low-performing areas to ensure that all targeted persons are vaccinated. Case-based measles surveillance, although improving in most countries, does not uniformly satisfy the minimum performance indicators recommended by WPRO. Of particular concern are the heterogeneity of reporting rates at the subnational level, and the failure to collect specimens or establish epidemiologic linkages through contact tracing and additional case-finding in several countries, resulting in large numbers of clinically confirmed cases whose actual case status remains uncertain. Surveillance priorities include increasing suspected case detection so that at least 80% of second-level administrative units report at least 1 discarded measles case per 100,000 population, conducting adequate investigations of R80% of suspected cases and collecting adequate specimens from R80% of reported suspected cases. In addition, contact tracing and additional case finding, as well as collection of specimens for virus detection from suspected cases likely to be measles, are critically important elements of measles surveillance, particularly when incidence decreases to ,10 cases per million population. Case-based surveillance data should be analyzed and surveillance performance monitored using standardized indicators at national and subnational levels. The excellence of the measles laboratory network will become increasingly important for the accurate classification of suspected measles cases and genetic sequencing of measles strains. The Western Pacific Region is closing in on its 2012 goal. However, the final stretch will require additional funding and increased political commitment at every level. Measles elimination is a worthwhile investment of public health resources, as it provides a number of benefits to child health and immunization and health systems development. First, measles immunization prevents increased susceptibility to and mortality from pneumonia and diarrhea that lasts for months following measles infection. Diarrhea and pneumonia cause 36% of deaths among children aged ,5 years globally, and 31% in the Western Pacific Region. Second, the need to achieve 95% coverage with 2 doses of MCV requires program managers at every level to strengthen routine immunization and health service coverage and quality using strategies recommended in the Global Immunization Vision and Strategy 2006-2015 [15] . Third, administering MCV2 during the second year of life creates a platform for other interventions such as DTP4, Hib4, OPV4, vitamin A, deworming medicine, and growth monitoring. Fourth, establishing school-entry measles immunization requirements provides an opportunity to ensure fully immunized status of children with all recommended vaccines, decrease child absenteeism from school and parental absenteeism from work, and strengthen collaboration between health and education ministries, establishing relationships that promote school health. Finally, the need to systematically report, analyze, interpret and feedback data and monitoring performance for case-based measles surveillance strengthens surveillance, data management and monitoring systems overall. To realize these gains, intensified advocacy and social mobilization must transform measles elimination from a health initiative to a national priority in member states.
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